Literature DB >> 6348107

Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis.

S C Dilsaver, Z Kronfol, J C Sackellares, J F Greden.   

Abstract

The authors present case examples of the various antidepressant withdrawal syndromes. Substantial evidence supports the contention that these syndromes result from cholinergic overdrive; thus, they may have a common pathophysiological basis. Even paradoxical reactions on antidepressant withdrawal, such as mania, are consistent with the cholinergic overdrive hypothesis. If the cholinergic overdrive hypothesis of affective illness. The cholinergic overdrive hypothesis is both of considerable heuristic value and is further testable by the study of the tonic and phasic aspects of sleep and neuroendocrine parameters in the withdrawal state.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6348107

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  7 in total

Review 1.  Continuation and maintenance therapy with antidepressive agents. An overview of research.

Authors:  A J Loonen; G J Zwanikken
Journal:  Pharm Weekbl Sci       Date:  1990-08-24

2.  Recognition and management of antidepressant discontinuation syndrome.

Authors:  Venkat Bhat; Sidney H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2017-06       Impact factor: 6.186

3.  Effect of imipramine treatment on changes in heart rate and blood pressure during postural and isometric handgrip tests.

Authors:  V K Yeragani; P Meiri; R Balon; R Pohl; S Golec
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Tranylcypromine withdrawal phenomena.

Authors:  M T Halle; S C Dilsaver
Journal:  J Psychiatry Neurosci       Date:  1993-01       Impact factor: 6.186

Review 5.  Withdrawal phenomena associated with antidepressant and antipsychotic agents.

Authors:  S C Dilsaver
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 6.  Antidepressant discontinuation syndromes.

Authors:  P M Haddad
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

7.  Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation-Is It Feasible to Develop Evidence-Based Guidelines?

Authors:  Graham Blackman; Ebenezer Oloyede; Mark Horowitz; Robert Harland; David Taylor; James MacCabe; Philip McGuire
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 9.306

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.